Lv71
3400 积分 2022-11-05 加入
Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies
7天前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
3个月前
已关闭
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
3个月前
已关闭
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
3个月前
已完结
Experiences of Teaching and Learning Pediatric Pain Management in Ghana
3个月前
已完结
TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma
3个月前
已完结
Selected pharmacologic characteristics of idarubicin and idarubicinol
5个月前
已关闭
Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial
5个月前
已完结
皖公网安备34019202002308
